Hussman Strategic Advisors Inc. Purchases Shares of 42,000 DexCom, Inc. $DXCM

Hussman Strategic Advisors Inc. acquired a new position in DexCom, Inc. (NASDAQ:DXCM) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 42,000 shares of the medical device company’s stock, valued at approximately $2,826,000.

Several other hedge funds have also recently made changes to their positions in DXCM. Andra AP fonden purchased a new stake in DexCom in the second quarter worth $26,000. Twin Peaks Wealth Advisors LLC purchased a new position in DexCom during the 2nd quarter valued at $26,000. SJS Investment Consulting Inc. raised its holdings in DexCom by 4,800.0% in the 3rd quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock worth $26,000 after purchasing an additional 384 shares in the last quarter. Financial Consulate Inc. purchased a new stake in shares of DexCom in the 3rd quarter worth about $29,000. Finally, Sound Income Strategies LLC lifted its position in shares of DexCom by 83.8% in the 3rd quarter. Sound Income Strategies LLC now owns 625 shares of the medical device company’s stock worth $43,000 after purchasing an additional 285 shares during the period. 97.75% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. Piper Sandler set a $75.00 price target on shares of DexCom and gave the stock a “buy” rating in a research note on Friday, October 31st. Robert W. Baird set a $82.00 target price on DexCom in a report on Friday, October 31st. Canaccord Genuity Group set a $99.00 target price on DexCom and gave the company a “buy” rating in a research note on Friday, October 31st. Barclays lowered DexCom from an “equal weight” rating to an “underweight” rating and dropped their price target for the company from $80.00 to $71.00 in a research report on Monday, January 12th. Finally, Sanford C. Bernstein reiterated an “outperform” rating and issued a $86.00 price objective (up previously from $84.00) on shares of DexCom in a report on Friday, January 9th. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, four have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $86.30.

Insider Buying and Selling

In related news, Director Bridgette P. Heller sold 1,012 shares of the company’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $58.07, for a total value of $58,766.84. Following the transaction, the director owned 27,031 shares in the company, valued at $1,569,690.17. The trade was a 3.61% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Jacob Steven Leach acquired 18,200 shares of DexCom stock in a transaction on Monday, November 10th. The shares were purchased at an average price of $55.04 per share, with a total value of $1,001,728.00. Following the completion of the purchase, the chief operating officer owned 331,697 shares in the company, valued at $18,256,602.88. This represents a 5.81% increase in their position. The SEC filing for this purchase provides additional information. Insiders have sold a total of 7,866 shares of company stock worth $448,177 in the last quarter. Corporate insiders own 0.32% of the company’s stock.

DexCom Stock Performance

DexCom stock opened at $73.67 on Wednesday. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $93.25. The company has a quick ratio of 1.38, a current ratio of 1.56 and a debt-to-equity ratio of 0.45. The company has a market capitalization of $28.73 billion, a P/E ratio of 40.93, a PEG ratio of 1.32 and a beta of 1.48. The stock’s 50 day moving average is $66.98 and its 200 day moving average is $70.91.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, October 30th. The medical device company reported $0.61 EPS for the quarter, topping the consensus estimate of $0.57 by $0.04. DexCom had a return on equity of 30.65% and a net margin of 15.96%.The business had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.18 billion. During the same period in the previous year, the company posted $0.45 earnings per share. The company’s revenue for the quarter was up 21.6% compared to the same quarter last year. On average, equities research analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.